Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period
- 133 Downloads
Buprenorphine has a long duration of action that allows less than daily dosing for opioid dependence, but pharmacologic characterization of buprenorphine’s duration of effects over multiple days is incomplete.
This study assessed opioid blockade and spontaneous withdrawal effects of buprenorphine/naloxone (B/N) over a 98-h period.
Materials and methods
Residential opioid-dependent volunteers (n = 8) were maintained, in randomized sequence, on each of three different daily sublingual B/N doses (8/2, 16/4, 32/8 mg). After 2 weeks on each maintenance dose, participants underwent challenge sessions on each weekday for 1 week. Challenges consisted of within-session, ascending dose administration of IM hydromorphone (H: 0, 6, and 12 mg). During that week, active B/N dose was given only on Monday; double-blind placebo was administered on the remaining weekdays. Thus, these sessions assessed the extent of both opioid blockade and spontaneous withdrawal at 2, 26, 50, 74, and 98 h after the last active B/N dose.
All three maintenance doses provided substantial but incomplete blockade against opioid agonist effects for 98 h. The extent of blockade diminished steadily but modestly over this time and did not differ as a function of B/N maintenance dose. In general, participants did not report marked spontaneous opioid withdrawal, although mild withdrawal effects were observed as time since the last active B/N dose increased. However, withdrawal did not differ as a function of B/N maintenance dose.
These findings suggest that B/N doses greater than 8/2 mg provide minimal incremental value in terms of opioid blockade and withdrawal suppression.
KeywordsBuprenorphine Dependence Hydromorphone Naloxone Opioid
Supported by US Public Health Service Scientist Development Award K02 DA00332 and R01 DA08045 from the National Institute on Drug Abuse.
- APA (2000) Diagnostic and statistical manual of mental disorders (text revision), 4th edn. American Psychiatric Association, WashingtonGoogle Scholar
- Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In: Martin WR (ed) Drug addiction I. Springer, Berlin Heidelberg New York, pp 197–258Google Scholar
- Kolb L, Himmelsbach CK (1938) Clinical studies of drug addiction. III. A critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Am J Psychiatry 94:759–799Google Scholar
- McLeod D, Griffiths RR, Bigelow GE, Yingling J (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 14:463–466Google Scholar
- McQuay HJ, Moore RA (1995) Buprenorphine kinetics in humans. In: Cowan A, Lewis JW (eds) Buprenorphine: combatting drug abuse with a unique opioid. Wiley, New York, pp 137–147Google Scholar